Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies

K Dahal, S Kunwar, J Rijal, P Schulman, J Lee - Chest, 2016 - Elsevier
Background The use of warfarin in patients with atrial fibrillation (AF) and chronic kidney
disease (CKD) can be problematic because of increased bleeding risk. We performed a …

Pathophysiology of atrial fibrillation and chronic kidney disease

WY Ding, D Gupta, CF Wong… - Cardiovascular research, 2021 - academic.oup.com
Atrial fibrillation (AF) and chronic kidney disease (CKD) are closely related conditions with
shared risk factors. The growing prevalence of both AF and CKD indicates that more patients …

2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart …

Writing Committee Members, JA Joglar… - Journal of the American …, 2024 - jacc.org
Abstract Aim The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management
of Patients With Atrial Fibrillation” provides recommendations to guide clinicians in the …

Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report

GYH Lip, A Banerjee, G Boriani, C en Chiang, R Fargo… - Chest, 2018 - Elsevier
Background The risk of stroke is heterogeneous across different groups of patients with atrial
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …

Chronic kidney disease and arrhythmias: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference

MP Turakhia, PJ Blankestijn, JJ Carrero… - European heart …, 2018 - academic.oup.com
Patients with chronic kidney disease (CKD) are predisposed to heart rhythm disorders,
including atrial fibrillation (AF)/atrial flutter, supraventricular tachycardias, ventricular …

Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial

EA Bohula, RP Giugliano, CT Ruff, JF Kuder… - Circulation, 2016 - Am Heart Assoc
Background: Edoxaban, an oral factor Xa inhibitor with 50% renal clearance, was
noninferior to well-managed warfarin for stroke or systemic embolism (S/SE) prevention and …

Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study

AN Bonde, GYH Lip, AL Kamper, PR Hansen… - Journal of the American …, 2014 - jacc.org
Background: The balance between stroke reduction and increased bleeding associated with
antithrombotic therapy among patients with atrial fibrillation (AF) and chronic kidney disease …

Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis

MS Randhawa, R Vishwanath, MP Rai… - JAMA network …, 2020 - jamanetwork.com
Importance Several studies have examined the role of warfarin in preventing strokes in
patients with atrial fibrillation and end-stage renal disease; however, the results remain …

[HTML][HTML] 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation

CE Chiang, K Okumura, S Zhang, TF Chao, CW Siu… - Journal of arrhythmia, 2017 - Elsevier
Atrial fibrillation (AF) is the most common sustained arrhythmia, causing a 2-fold increase in
mortality and a 5-fold increase in stroke. The Asian population is rapidly aging, and in 2050 …

The Stockholm CREAtinine Measurements (SCREAM) project: fostering improvements in chronic kidney disease care

JJ Carrero, CG Elinder - Journal of internal medicine, 2022 - Wiley Online Library
Abstract SCREAM (Stockholm CREAtinine Measurements project) was initiated in 2010 in
collaboration with the healthcare provider of Stockholm County healthcare to quantify …